Emma Guttman-Yassky
#126,580
Most Influential Person Now
Researcher
Emma Guttman-Yassky's AcademicInfluence.com Rankings
Emma Guttman-Yasskyphilosophy Degrees
Philosophy
#5961
World Rank
#8902
Historical Rank
Logic
#3161
World Rank
#4280
Historical Rank
Emma Guttman-Yasskybiology Degrees
Biology
#8055
World Rank
#11070
Historical Rank
Immunology
#446
World Rank
#463
Historical Rank
Download Badge
Philosophy Biology
Emma Guttman-Yassky's Degrees
- Doctorate Medicine University of Medicine and Dentistry of New Jersey
Why Is Emma Guttman-Yassky Influential?
(Suggest an Edit or Addition)According to Wikipedia, Emma Guttman-Yassky is the System Chair of the Department of Dermatology and Waldman professor of dermatology and immunology at the Icahn School of Medicine at Mount Sinai in New York. She is also director of its center for excellence in eczema, its occupational dermatitis clinic, and its inflammatory skin disease laboratory.
Emma Guttman-Yassky's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. (2016) (1154)
- Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. (2014) (1041)
- Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways (2008) (770)
- Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. (2012) (672)
- IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. (2009) (578)
- Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. (2011) (548)
- Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. (2016) (434)
- The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. (2015) (400)
- The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. (2017) (376)
- Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. (2013) (361)
- Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. (2011) (357)
- Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. (2014) (356)
- Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. (2014) (355)
- Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis1 (2008) (337)
- Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis (2019) (321)
- Contrasting pathogenesis of atopic dermatitis and psoriasis--part I: clinical and pathologic concepts. (2011) (314)
- Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. (2009) (284)
- Contrasting pathogenesis of atopic dermatitis and psoriasis--part II: immune cell subsets and therapeutic concepts. (2011) (284)
- Atopic dermatitis endotypes and implications for targeted therapeutics. (2019) (282)
- Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder. (2017) (274)
- Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. (2016) (270)
- Treatment of atopic dermatitis with tralokinumab, an anti–IL‐13 mAb (2019) (250)
- Baricitinib in adult patients with moderate‐to‐severe atopic dermatitis: A phase 2 parallel, double‐blinded, randomized placebo‐controlled multiple‐dose study (2018) (237)
- Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. (2009) (236)
- Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. (2007) (228)
- Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? (2017) (223)
- Conjunctivitis in dupilumab clinical trials (2019) (220)
- Efficacy and safety of fezakinumab (an IL‐22 monoclonal antibody) in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double‐blind, phase 2a trial (2018) (210)
- Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials (2020) (207)
- RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. (2015) (206)
- Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis (2019) (197)
- Type 2 immunity in the skin and lungs (2020) (195)
- Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. (2014) (195)
- Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. (2011) (188)
- Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. (2017) (182)
- Efficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis (2017) (180)
- Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. (2013) (179)
- Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. (2015) (174)
- Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. (2018) (173)
- Atopic dermatitis in diverse racial and ethnic groups—Variations in epidemiology, genetics, clinical presentation and treatment (2018) (172)
- Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis. (2020) (168)
- The translational revolution and use of biologics in patients with inflammatory skin diseases. (2015) (168)
- Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial. (2019) (168)
- Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. (2015) (167)
- Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)* (2020) (167)
- Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skin (2014) (160)
- Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. (2015) (159)
- Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. (2015) (157)
- The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins (2017) (156)
- TNF-α downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-α antagonists to improve skin barrier. (2011) (155)
- Early‐onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22‐centered inflammation and lipid alterations (2018) (153)
- IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model (2014) (148)
- Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications. (2014) (146)
- Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis (2020) (142)
- When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council (2017) (138)
- Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. (2014) (137)
- An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease. (2017) (131)
- Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment (2018) (130)
- An IL‐17–dominant immune profile is shared across the major orphan forms of ichthyosis (2017) (126)
- JAK Inhibitors for Atopic Dermatitis: An Update (2018) (123)
- Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. (2017) (121)
- Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials (2021) (120)
- Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment. (2007) (116)
- Racial differences in atopic dermatitis. (2019) (115)
- Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways (2015) (113)
- Immunologic, microbial, and epithelial interactions in atopic dermatitis. (2018) (113)
- Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets. (2011) (112)
- Baseline IL‐22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab (2018) (111)
- Petrolatum: Barrier repair and antimicrobial responses underlying this "inert" moisturizer. (2016) (110)
- Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement (2018) (109)
- Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics (2015) (106)
- Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation. (2019) (104)
- GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. (2019) (103)
- Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions” (2019) (94)
- New pathogenic and therapeutic paradigms in atopic dermatitis. (2015) (93)
- IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis (2019) (92)
- Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. (2016) (90)
- New era of biologic therapeutics in atopic dermatitis (2013) (89)
- Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches (2019) (88)
- Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling (2016) (85)
- Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids (2006) (85)
- Drug evaluation review: dupilumab in atopic dermatitis. (2015) (81)
- Use of Tape Strips to Detect Immune and Barrier Abnormalities in the Skin of Children With Early-Onset Atopic Dermatitis. (2019) (79)
- Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. (2020) (79)
- New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines. (2019) (79)
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm (2017) (77)
- The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study† (2019) (76)
- Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. (2020) (74)
- Biomarkers in atopic dermatitis - a review on behalf of the international eczema council. (2021) (73)
- Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. (2010) (72)
- Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation. (2009) (71)
- Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis. (2016) (71)
- A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis. (2019) (70)
- The autologous serum skin test in a cohort of chronic idiopathic urticaria patients compared to respiratory allergy patients and healthy individuals (2007) (68)
- Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism. (2016) (67)
- Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis. (2015) (66)
- Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature (2019) (63)
- Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. (2019) (62)
- Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness. (2008) (62)
- Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis (2018) (62)
- The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature. (2020) (61)
- A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis. (2016) (59)
- Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research (2007) (56)
- Biomarkers of alopecia areata disease activity and response to corticosteroid treatment (2016) (56)
- Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. (2015) (55)
- Nonlesional atopic dermatitis skin shares similar T‐cell clones with lesional tissues (2017) (55)
- Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin. (2015) (55)
- Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial. (2019) (55)
- Atopic dermatitis in Chinese patients shows TH2/TH17 skewing with psoriasiform features. (2018) (54)
- Atopic dermatitis: pathogenesis (2017) (54)
- Human and computational models of atopic dermatitis: A review and perspectives by an expert panel of the International Eczema Council (2018) (54)
- Th2/Th1 Cytokine Imbalance Is Associated With Higher COVID-19 Risk Mortality (2021) (52)
- Oral JAK/SYK-inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis. (2019) (51)
- The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease. (2019) (51)
- An update on the microbiology, immunology and genetics of seborrheic dermatitis (2020) (50)
- Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? (2014) (50)
- Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE-AD5). (2021) (49)
- Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib (2020) (48)
- Endophenotypic Variations of Atopic Dermatitis by Age, Race, and Ethnicity. (2020) (48)
- The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: Immunophenotyping and response to ustekinumab (2017) (47)
- Molecular signatures order the potency of topically applied anti‐inflammatory drugs in patients with atopic dermatitis (2017) (47)
- Resolution of orofacial granulomatosis with amalgam removal (2003) (47)
- Phase 2 Randomized, Double-blind Study of IL-17-Targeting with Secukinumab in Atopic Dermatitis. (2020) (47)
- Global Allergy Forum and 3rd Davos Declaration 2015 (2016) (46)
- IL-17C: A Unique Epithelial Cytokine with Potential for Targeting across the Spectrum of Atopic Dermatitis and Psoriasis. (2018) (46)
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. (2021) (45)
- Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood (2019) (43)
- Identification of unique proteomic signatures in allergic and non‐allergic skin disease (2017) (43)
- A possible role for IL-17A in establishing Th2 inflammation in murine models of atopic dermatitis (2014) (43)
- Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion (2019) (43)
- Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial (2019) (43)
- Alterations in B‐cell subsets in pediatric patients with early atopic dermatitis (2017) (42)
- The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition (2018) (42)
- Obesity alters pathology and treatment response in inflammatory disease (2022) (41)
- The Major Orphan Forms of Ichthyosis Are Characterized by Systemic T-Cell Activation and Th-17/Tc-17/Th-22/Tc-22 Polarization in Blood. (2018) (41)
- KAPOSI'S SARCOMA–ASSOCIATED HERPESVIRUS: Clinical, Diagnostic, and Epidemiological Aspects (2005) (40)
- A Phase 2b Dose-Ranging Efficacy and Safety Study of Tralokinumab in Adult Patients with Moderate to Severe Atopic Dermatitis (2018) (40)
- The Unique Molecular Signatures of Contact Dermatitis and Implications for Treatment (2019) (39)
- Alopecia areata is characterized by expansion of circulating Th2/Tc2/Th22, within the skin‐homing and systemic T‐cell populations (2018) (39)
- Serum from Asian patients with atopic dermatitis is characterized by TH2/TH22 activation, which is highly correlated with nonlesional skin measures. (2018) (38)
- Attenuated neutrophil axis in atopic dermatitis compared to psoriasis reflects TH17 pathway differences between these diseases. (2013) (38)
- ΔNp63 regulates IL-33 and IL-31 signaling in atopic dermatitis (2016) (37)
- Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers (2020) (37)
- Molecular and Cellular Profiling of Scalp Psoriasis Reveals Differences and Similarities Compared to Skin Psoriasis (2016) (37)
- Tape strips from early‐onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin (2020) (37)
- Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect. (2021) (37)
- Arginase1 Deficiency in Monocytes/Macrophages Upregulates Inducible Nitric Oxide Synthase To Promote Cutaneous Contact Hypersensitivity (2017) (37)
- Single-cell analysis of human skin identifies CD14+ type 3 dendritic cells co-producing IL1B and IL23A in psoriasis (2021) (36)
- Mild atopic dermatitis lacks systemic inflammation, and shows reduced non-lesional skin abnormalities. (2020) (35)
- What's New in Atopic Dermatitis. (2019) (35)
- Circulating CLA+ T cells in atopic dermatitis and their possible role as peripheral biomarkers (2017) (34)
- The ‘omics’ revolution: redefining the understanding and treatment of allergic skin diseases (2016) (34)
- Prostaglandin E2 stimulates adaptive IL‐22 production and promotes allergic contact dermatitis (2018) (34)
- Successful use of ustekinumab therapy in refractory severe atopic dermatitis (2014) (33)
- Mechanisms of contact sensitization offer insights into the role of barrier defects versus intrinsic immune abnormalities as drivers of atopic dermatitis (2013) (33)
- Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program (2021) (33)
- Atopic dermatitis keratinocytes exhibit normal T(H)17 cytokine responses. (2010) (33)
- RNA Sequencing Keloid Transcriptome Associates Keloids With Th2, Th1, Th17/Th22, and JAK3-Skewing (2020) (33)
- CARD14 alterations in Tunisian patients with psoriasis and further characterization in European cohorts (2016) (33)
- A novel therapeutic paradigm for patients with extensive alopecia areata (2016) (32)
- Increased cardiovascular and atherosclerosis markers in blood of older atopic dermatitis patients. (2019) (32)
- Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity (2017) (32)
- Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines (2020) (32)
- The molecular features of normal and atopic dermatitis skin in infants, children, adolescents and adults. (2021) (31)
- Keloid lesions show increased IL‐4/IL‐13 signaling and respond to Th2‐targeting dupilumab therapy (2019) (31)
- Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata (2018) (31)
- A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata (2018) (30)
- Residual genomic signature of atopic dermatitis despite clinical resolution with narrow-band UVB. (2013) (30)
- The skin as an immune organ: Tolerance versus effector responses and applications to food allergy and hypersensitivity reactions. (2019) (30)
- An integrated model of alopecia areata biomarkers highlights both TH1 and TH2 upregulation. (2018) (30)
- Accelerated T-cell activation and differentiation of polar subsets characterizes early atopic dermatitis development. (2016) (30)
- Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients (2021) (29)
- Acute rhabdomyolysis and myoglobinuria associated with isotretinoin treatment. (2003) (28)
- Efficacy of biologics in atopic dermatitis (2020) (28)
- Infection with Kaposi's sarcoma-associated herpesvirus among families of patients with classic Kaposi's sarcoma. (2005) (28)
- Correction to: JAK Inhibitors for Atopic Dermatitis: An Update (2019) (28)
- Epidemiology of classic Kaposi's sarcoma in the Israeli Jewish population between 1960 and 1998 (2003) (28)
- Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses’ Health Study 2 (2017) (27)
- The IL-4, IL-13 and IL-31 pathways in atopic dermatitis (2021) (27)
- Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic vs. regulatory immune cell subsets. (2021) (26)
- SARS‐CoV‐2 receptor ACE2 protein expression in serum is significantly associated with age (2020) (26)
- Cross-sectional study of blood biomarkers of patients with moderate-to-severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation. (2020) (26)
- Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients. (2019) (26)
- Kallikrein 7 promotes atopic dermatitis-associated itch independently of skin inflammation. (2019) (25)
- Whole-Genome Sequencing Identifies STAT4 as a Putative Susceptibility Gene in Classic Kaposi Sarcoma. (2015) (25)
- COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab (2021) (25)
- Efficacy and safety of dupilumab for moderate‐to‐severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines (2020) (24)
- Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases. (2019) (24)
- Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. (2008) (23)
- Effect of short-term liver X receptor activation on epidermal barrier features in mild to moderate atopic dermatitis: A randomized controlled trial. (2018) (23)
- Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence. (2014) (23)
- Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing (2020) (23)
- Assessing the current treatment of atopic dermatitis: Unmet needs. (2017) (23)
- Cutaneous p38 mitogen-activated protein kinase activation triggers psoriatic dermatitis. (2019) (23)
- Systemic therapies in atopic dermatitis: The pipeline. (2017) (22)
- Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma (2021) (22)
- Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis (2022) (22)
- Real-world persistence with dupilumab among adults with atopic dermatitis. (2020) (21)
- Alopecia Areata is Associated with Atopic Diathesis; Results from a Population-Based Study of 51,561 Patients. (2020) (21)
- Dust mite induces multiple polar T cell axes in human skin (2017) (21)
- Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways (2020) (20)
- Atopic dermatitis endotypes based on allergen sensitization, reactivity to Staphylococcus aureus antigens, and underlying systemic inflammation. (2019) (19)
- Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases. (2018) (19)
- Topical agents for the treatment of atopic dermatitis (2019) (18)
- Relationship between human herpesvirus 8 loads and disease stage in classic Kaposi sarcoma patients. (2007) (18)
- Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata (2017) (18)
- Current and emerging biologic and small molecule therapies for atopic dermatitis (2019) (18)
- Early intervention and prevention of allergic diseases (2021) (17)
- Human telomerase RNA component expression in Spitz nevi, common melanocytic nevi, and malignant melanomas (2002) (17)
- Major differences in expression of inflammatory pathways in skin from different body sites of healthy individuals. (2019) (16)
- Phase 2 Randomized, Dose-Ranging Trial of CTP-543, a Selective Janus Kinase Inhibitor, in Moderate to Severe Alopecia Areata. (2022) (16)
- Vascular inflammation in moderate‐to‐severe atopic dermatitis is associated with enhanced Th2 response (2021) (15)
- Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis. (2021) (15)
- IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization (2014) (14)
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. (2021) (14)
- Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study (2020) (13)
- Clinical Relevance of Skin Pain in Atopic Dermatitis. (2020) (13)
- Patch testing of food allergens promotes Th17 and Th2 responses with increased IL‐33: a pilot study (2017) (13)
- Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE) (2022) (12)
- UPADACITINIB EFFECT ON PRURITUS IN MODERATE-TO-SEVERE ATOPIC DERMATITIS; FROM A PHASE 2B RANDOMIZED, PLACEBO-CONTROLLED TRIAL (2018) (12)
- Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum (2021) (12)
- Successful treatment of juvenile pityriasis rubra pilaris with ustekinumab in a 7-year-old girl (2018) (12)
- Secukinumab responses vary across the spectrum of congenital ichthyosis in adults (2022) (12)
- Comparing cutaneous molecular improvement with different treatments in atopic dermatitis patients. (2020) (11)
- Mapping atopic dermatitis and anti-IL-22 response signatures to Type 2-low severe neutrophilic asthma. (2021) (11)
- A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata (2022) (11)
- A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis. (2021) (11)
- Alopecia areata profiling shows T H 1, T H 2, and IL-23 cytokine activation without parallel T H 17/T H 22 skewing (2015) (11)
- 313 A pathogenic role for Th22/IL-22 in atopic dermatitis is established by a placebo-controlled trial with an anti IL-22/ILV-094 mAb (2017) (11)
- Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges (2020) (11)
- Changes in Skin and Nasal Microbiome and Staphylococcal Species Following Treatment of Atopic Dermatitis with Dupilumab (2021) (11)
- Tape-strips provide a minimally-invasive approach to track therapeutic response to topical corticosteroids in atopic dermatitis patients. (2020) (10)
- Improving evaluation of drugs in atopic dermatitis by combining clinical and molecular measures. (2020) (10)
- Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitisA phase 2b randomized study. (2020) (10)
- EAACI Biologicals Guidelines—dupilumab for children and adults with moderate‐to‐severe atopic dermatitis (2020) (10)
- Chronic hand eczema understanding has ramifications on clinical management (2020) (10)
- 559 ASN002 a dual oral inhibitor of JAK/SYK signaling improves clinical outcomes and associated cutaneous inflammation in moderate-to-severe atopic dermatitis patients (2018) (10)
- The role of circulating eosinophils on COVID‐19 mortality varies by race/ethnicity (2020) (10)
- Use of 308 nm excimer laser for the treatment of chronic hand and foot eczema (2016) (10)
- The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris. (2021) (9)
- Immune and barrier characterization of atopic dermatitis skin phenotype in Tanzanian patients. (2021) (9)
- Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey‐based position statement (2019) (9)
- A preliminary 18F-FDG-PET/MRI study shows increased vascular inflammation in moderate-to-severe atopic dermatitis. (2020) (8)
- Ustekinumab as therapy for psoriasis in a 2‐year‐old girl (2016) (8)
- Monoclonal antibodies for the treatment of atopic dermatitis (2018) (8)
- Granuloma annulare skin profile shows activation of Th1, Th2, and JAK pathways. (2019) (8)
- A plea for standardization of confocal microscopy and optical coherence tomography parameters to evaluate physiological and para‐physiological skin conditions in cosmetic science (2021) (8)
- Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors. (2021) (8)
- 224 Successful use of secukinumab in an Asian patient with severe refractory atopic dermatitis (2016) (7)
- Evolution of pathologic T-cell subsets in atopic dermatitis from infancy to adulthood. (2019) (7)
- Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of three phase 3 randomized, double-blind, placebo-controlled trials. (2022) (7)
- Conjunctivitis in dupilumab clinical trials (2019) (7)
- IL-36 and IL-17A Cooperatively Induce a Psoriasis-like Gene Expression Response in Human Keratinocytes. (2021) (7)
- Psoriasis Treatments: A Review of the Current Research Pipeline (2011) (7)
- An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata (2021) (7)
- Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate‐to‐severe disease (2021) (7)
- Tralokinumab for the Treatment of Atopic Dermatitis (2021) (7)
- 224 Successful use of secukinumab in an Asian patient with severe refractory atopic dermatitis (2016) (7)
- Intrinsic atopic dermatitis ( AD ) shows similar Th 2 and higher Th 17 immune activation compared to extrinsic AD (2014) (7)
- Multi-ethnic genome-wide and HLA association study of total serum IgE. (2021) (6)
- A Nitric Oxide-releasing Topical Medication as a Potential Treatment Option for Atopic Dermatitis Through Antimicrobial and Anti-inflammatory Activity. (2020) (6)
- Transcriptomic Analysis of the Major Orphan Ichthyosis Subtypes Reveals Shared Immune and Barrier Signatures. (2022) (6)
- The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals (2022) (6)
- EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old (2021) (6)
- Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways (2015) (6)
- Emerging Systemic Therapeutic Biologics and Small Molecules for Atopic Dermatitis: How to Decide Which Treatment Is Right for Your Patients. (2021) (6)
- The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis (2022) (6)
- Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double‐blind, placebo‐controlled Phase 2 trial (2022) (6)
- Dupilumab improves clinical scores in children and adolescents with moderate-to-severe atopic dermatitis: A real-world, single-center study. (2022) (5)
- Author Correction: The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins (2018) (5)
- Transcriptomic Profiling of Tape-Strips From Moderate to Severe Atopic Dermatitis Patients Treated With Dupilumab (2021) (5)
- 102 Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Patients With Atopic Dermatitis (2019) (5)
- Chronic Hand Eczema Guidelines From an Expert Panel of the International Eczema Council (2020) (5)
- Distinct skin microbiome community structures in congenital ichthyosis (2022) (5)
- Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement (2018) (5)
- Maintenance, withdrawal and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial. (2021) (5)
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1) (2019) (5)
- 453 GBR 830 induces progressive and sustained changes in atopic dermatitis biomarkers in patient skin lesions (2018) (5)
- P573 The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications (2022) (5)
- Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study (2019) (5)
- The erythema Q‐score, an imaging biomarker for redness in skin inflammation (2020) (4)
- Absence of Kaposi's sarcoma-associated herpesvirus in lesions of mycosis fungoides in patients with concomitant Kaposi's sarcoma. (2004) (4)
- International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale (2020) (4)
- High‐dimensional analysis defines multicytokine T‐cell subsets and supports a role for IL‐21 in atopic dermatitis (2021) (4)
- New Therapies for Atopic Dermatitis: How will they impact skin care? (2022) (4)
- 039 Early onset pediatric atopic dermatitis skin phenotype is Th2, but also Th17-polarized (2016) (4)
- Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2) (2020) (4)
- Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies. (2022) (4)
- Selective sweep for an enhancer involucrin allele identifies skin barrier adaptation out of Africa (2021) (4)
- The impact of dupilumab treatment on SARS-CoV-2/COVID-19 antibody responses in atopic dermatitis patients (2022) (3)
- 1024 Upadacitinib treatment of atopic dermatitis patients leads to reductions in epidermal hyperplasia and cellular infiltrates (2019) (3)
- 058 Variable TH2/TH17-skewing places Chinese atopic dermatitis and psoriasis on an inflammatory spectrum (2018) (3)
- Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials (2020) (3)
- Rapidly progressive classic Kaposi sarcoma in an adolescent: response to interferon alfa therapy and biological correlates (2006) (3)
- C10orf99/GPR15L Regulates Proinflammatory Response of Keratinocytes and Barrier Formation of the Skin (2022) (3)
- 1205 Vitiligo lesional and non-lesional skin shows polar cytokine activation (2018) (3)
- Analysis of alopecia areata surveys suggests a threshold for improved patient‐reported outcomes (2022) (3)
- Tape strips capture atopic dermatitis‐related changes in nonlesional skin throughout maturation (2022) (3)
- 373 Dupilumab improves clinical atopic dermatitis parameters and modulates specific IgEs and Staphylococcus aureus abundance (2016) (3)
- TH2 cytokines and Staphylococcus aureus cooperatively induce atopic dermatitis‐like transcriptomes (2021) (3)
- Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology (2020) (3)
- 1322 Molecular profiling of frontal fibrosing alopecia (FFA) reveals TH1 and JAK-STAT up-regulation with no suppression of hair keratins (2018) (3)
- Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata (2022) (3)
- Comorbidities of atopic dermatitis-what does the evidence say? (2023) (3)
- Supplementary material : Atopic dermatitis in Chinese patients shows T H 2/T H 17 skewing with psoriasiform features (2018) (3)
- Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV–VI (2022) (3)
- Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery (2022) (3)
- Eosinophil Count and Serum Immunoglobulin E Levels in Atopic Dermatitis: Analysis of Upadacitinib Phase 2 Study Findings: 376 (2019) (3)
- Compléments : The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased T H 17 polarization (2015) (3)
- Skin TARC/CCL17 increase precedes the development of childhood atopic dermatitis. (2022) (2)
- Atopic dermatitis (AD) keratinocytes exhibit normal Th17 cytokine responses (2014) (2)
- An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study (2022) (2)
- Results from a randomized, double-blind, placebo-controlled, exploratory, multicenter study of GBR 830 in adult patients with moderate-to-severe atopic dermatitis (2018) (2)
- 563 ATx201 modulates biomarkers of skin barrier function and cutaneous inflammation in patients with moderate atopic dermatitis (2020) (2)
- COVID-19 in tralokinumab-treated patients with moderate-to- severe atopic dermatitis: case series from the ECZTEND long- term extension trial (2021) (2)
- Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseases (2022) (2)
- Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement. (2021) (2)
- Skin microbiome and its association with host cofactors in determining atopic dermatitis severity (2022) (2)
- An enhancer:involucrin regulatory module impacts human skin barrier adaptation out-of-Africa and modifies atopic dermatitis risk (2019) (2)
- Identifying Genetic Determinants of Atopic Dermatitis and Bacterial Colonization Using Whole Genome Sequencing (2015) (2)
- 058 Non-lesional atopic dermatitis skin shares similar T cell clones with lesional tissues (2017) (2)
- Exogenous Factors in Atopic Dermatitis (2004) (2)
- Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. (2023) (2)
- Proteomic signatures of inflammatory skin diseases: a focus on atopic dermatitis (2021) (2)
- Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma? (2019) (2)
- 1071 Age-specific changes in the atopic dermatitis molecular phenotype (2018) (2)
- Correspondence (2003) (2)
- Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program (2021) (2)
- Molecular signatures order the potency of topically applied anti-inflammatory drugs in atopic dermatitis patients (2017) (2)
- Disease Characteristics, Comorbidities, Treatment Patterns and Quality of Life Impact in Children <12 Years Old with Atopic Dermatitis: Interim Results from the PEDISTAD Real-World Registry. (2022) (2)
- Candidate Predisposition Variants in Kaposi Sarcoma as Detected by Whole-Genome Sequencing (2019) (2)
- Current emerging and investigational drugs for the treatment of chronic hand eczema (2022) (2)
- Revolutionizing Atopic Dermatitis, 5 April 2020 (2020) (2)
- Systemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in Practice (2019) (2)
- 27523 Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis (AD) from the phase 2 and phase 3 clinical trial program (2021) (2)
- 434 Baseline IL-22 expression in atopic dermatitis patients stratifies therapeutic responses to fezakinumab (2018) (2)
- Spesolimab, an anti‐interleukin‐36 receptor antibody, in patients with moderate‐to‐severe atopic dermatitis: Results from a multicentre, randomized, double‐blind, placebo‐controlled, phase IIa study (2022) (2)
- Priority research questions in atopic dermatitis: an International Eczema Council eDelphi consensus (2021) (1)
- Multiscale analysis of acne connects molecular subnetworks with disease status (2019) (1)
- 299 Oral difelikefalin improves itch and inflammatory biomarkers in atopic dermatitis subjects with moderate-to-severe pruritus (2022) (1)
- O060 Cross-sectional study of disease control among adults with atopic dermatitis and impact on patient-reported burden (2016) (1)
- Response to "Comment on: 'When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council'". (2018) (1)
- 231 Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis (2016) (1)
- 695 Topical application of KPI-150, a potent inhibitor of Kv1.3 channels on effector memory T cells, demonstrates preclinical efficacy in atopic dermatitis model (2017) (1)
- 1285 Atopic dermatitis in African American patients is TH2/TH22-driven with TH1/TH17 attenuation and downregulation of loricrin (2018) (1)
- The evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective (2023) (1)
- 040 Th/Tc9 and Th/Tc17 pathways are augmented in moderate-to-extensive bullous pemphigoid patients and suppressed by bertilimumab (2019) (1)
- Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset (2022) (1)
- Gene Expression Profiling Associated with the Progression of Classic Kaposi's Sarcoma (2012) (1)
- Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. (2023) (1)
- 417 The molecular features of normal and atopic dermatitis skin in infants, children, adolescents and adults (2021) (1)
- Absence of Kaposi's sarcoma‐associated herpesvirus genome in adenocarcinoma of the colon in patients with concomitant Kaposi's sarcoma (2006) (1)
- Iconographies supplémentaires de l'article : Attenuated neutrophil axis in atopic dermatitis compared to psoriasis reflects T H 17 pathway differences between these diseases (2013) (1)
- Risk of anaphylaxis and conjunctivitis with tralokinumab in atopic dermatitis (2018) (1)
- Correction to: Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study (2020) (1)
- Atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity. (2017) (1)
- Reply to "Combined antibiotic, steroid, and moisturizer for atopic dermatitis: A 2-year case series of patient-reported outcomes". (2021) (1)
- Dupilumab in Moderate-to-Severe Atopic Dermatitis With or Without Comorbid Asthma: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 & 2) (2018) (1)
- Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis (2023) (1)
- Oral JAK Inhibitors for Atopic Dermatitis. (2023) (1)
- The Immunology of AD and its Reversibility with Broad Spectrum and Targeted Therapies (2017) (1)
- Burden of Disease and Unmet Needs in Atopic Dermatitis: Results From a Patient Survey. (2023) (1)
- Atopic dermatitis among children and adolescents in the Arctic region – a systematic review and meta‐analysis (2021) (1)
- 322 Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2) (2023) (1)
- LB1505 Dupilumab-mediated IL-4Rα blockade decreases Staphylococcus aureus colonization and increases microbial diversity in patients with Atopic Dermatitis (AD) (2018) (1)
- Evidence for Activity of GBR830 (Anti‐OX40) in Extrinsic and Intrinsic Atopic Dermatitis (AD) in a Phase 2a Study: 382 (2019) (1)
- The atopic dermatitis spectrum disorder. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes: an expert panel consensus statement (2021) (1)
- 544 A model to evaluate intra-patient differential effects of topical agents in atopic dermatitis (2016) (1)
- Reply to: “Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients” (2022) (1)
- 25854 Effects on type 2 immunity when specifically targeting the interleukin-13 cytokine with tralokinumab (2021) (1)
- IgG memory B cells expressing IL4R and FCER2 are associated with atopic diseases (2022) (1)
- The translational revolution in atopic dermatitis, and how it also translates to other inflammatory skin diseases. (2016) (1)
- Mechanisms of allergic diseases Cellular and molecular immunologic mechanisms in patients with atopic dermatitis (1)
- Chronic idiopathic urticaria: what is the meaning of skin reactivity to autologous serum? A response (2007) (1)
- 673 Real-world persistence with dupilumab among adults with atopic dermatitis (AD) (2019) (1)
- 692 Real-world effectiveness of dupilumab based on Investigator Global Assessment (IGA) and peak Pruritus Numerical Rating Scale (PNRS) scores (2019) (1)
- 586 Topical nitric oxide releasing therapy with 2% SB414 cream downregulated major gene expressions in patients with atopic dermatitis (2019) (1)
- 395 Disease severity and cutaneous inflammation in ichthyosis are linked to Th17 pathway activation (2016) (0)
- Interaction Between the R501X Filaggrin Mutation and Disease Severity Associates with Increased Staphylococcus Aureus Colonization in European American Subjects with Atopic Dermatitis (2016) (0)
- FRT – Fondation Rene Touraine (2014) (0)
- 199 The molecular signature of Eosinophilic Cellulitis correlates with the efficacy of baricitinib in a refractory patient (2021) (0)
- 850 Proteomic blood signature of African American patients with atopic dermatitis shows more prominent Th2 activation and Th1 attenuation compared to other ethnicities (2019) (0)
- 1291 Tralokinumab improves signs, symptoms, and key biomarkers in patients of different racial subgroups with atopic dermatitis (2023) (0)
- 386 Biomarkers of alopecia areata in blood reveal systemic immune and cardiovascular abnormalities (2020) (0)
- Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery (2022) (0)
- Oral Difelikefalin Reduces Pruritus in Atopic Dermatitis (2021) (0)
- The impact of dupilumab treatment on SARS‐CoV‐2 T cell responses in atopic dermatitis patients (2022) (0)
- 466 Early pediatric atopic dermatitis is a T-cell driven disease accompanied by a secondary B-cell activation (2016) (0)
- 1292 Molecular phenotyping of keloid skin samples suggests polar immune dysregulation (2023) (0)
- 399 Tralokinumab treatment modifies stratum corneum lipid composition in skin of adolescents with atopic dermatitis (2022) (0)
- 689 An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata (2021) (0)
- 693 Dust mite potently activates Th17/Th22 pathways and models multiple inflammatory skin conditions in humans (2017) (0)
- Non-lesional atopic dermatitis skin shares similar T-cell clones with lesional tissues Short title : T-cell receptor repertoire in lesional and non-lesional AD (2017) (0)
- 310 Efficacy and safety of abrocitinib in biologic-exposed versus biologic-naïve patients with moderate-to-severe atopic dermatitis (2022) (0)
- 648 The barrier abnormality of early-onset pediatric atopic dermatitis results from abnormalities in tight junctions and epidermal lipids, but not differentiation proteins (2018) (0)
- Efficacy and safety of dupilumab in children aged 6–11 years with inadequately controlled severe atopic dermatitis: Results from an open-label extension trial up to 1 year (2022) (0)
- Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Patients With Atopic Dermatitis (2019) (0)
- Distinct Features Identified in Adult Atopic Dermatitis Subjects Based on Age of Onset (2016) (0)
- Emerging Therapies and Potential for Personalized Medicine Approaches (2019) (0)
- Author Correction: The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins (2018) (0)
- 1215 Ritlecitinib, an oral dual JAK3/TEC family kinase inhibitor, induces differential changes in immunological protein levels across Fitzpatrick skin types (FST) in patients with active nonsegmental vitiligo (NSV) (2023) (0)
- Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress (2018) (0)
- 245 RNAseq profiling highlights immune and barrier differences among ichthyoses (2020) (0)
- Impact of Lebrikizumab on Patient-Reported Outcomes in Atopic Dermatitis: Prospective and Post Hoc Analyses of a Phase 2b Clinical Trial Demonstrate Clinically Meaningful Improvements (2020) (0)
- 668 An integrated model of alopecia areata biomarkers highlights TH1 and TH2 pathways (2019) (0)
- 052 Vitiligo is characterized by multi-axis T-cell activation in blood (2018) (0)
- 073 Th17 and Th22 polarization in ichthyosis blood correlates with disease severity and highlights its systemic nature (2017) (0)
- Atopic Dermatitis in Teenagers and Adults (2015) (0)
- Myeloid dendritic cells from human squamous cell carcinoma are poor stimulators of T cell proliferation (2010) (0)
- 256 Treatment of Netherton syndrome with dupilumab (2020) (0)
- 701 High dimensional peripheral blood immune cell profiling of atopic dermatitis patients unveiled IL21 cytokine activation (2019) (0)
- 297 Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis (2022) (0)
- Atopic dermatitis. (2007) (0)
- Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial (2022) (0)
- Proteomic characterization of atopic dermatitis blood from infancy to adulthood. (2023) (0)
- 495 Ichthyosis molecular fingerprinting shows profound Th17-skewing and a unique barrier gene expression pattern (2017) (0)
- Atopic Dermatitis in Adults: Pathophysiology and Emerging Treatments (2015) (0)
- Cytokines and Anticytokine Therapies in AD and Other Atopic Diseases (2018) (0)
- Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis (2023) (0)
- Familial Clustering of Classic (2004) (0)
- 294 Extensive alopecia areata is reversed by IL-12/23p40 cytokine antagonism (2016) (0)
- 012 Crisaborole ointment provides early relief of pruritus in two phase 3 clinical trials in patients with mild or moderate atopic dermatitis (2017) (0)
- 565 Improvement in skin inflammation and barrier function biomarkers with crisaborole treatment in atopic dermatitis (AD) (2019) (0)
- 440 Topical phosphodiesterase 4 (PDE4) inhibitor crisaborole (crisa) improves skin transcriptomic and proteomic biomarkers of mild-to-moderate AD towards normal skin (2022) (0)
- Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE). (2023) (0)
- 727 Keloids are associated with Th2, JAK3, and CCR9/CCL25 inflammation (2020) (0)
- Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort. (2022) (0)
- 822 RPT193, a CCR4 inhibitor, improves the inflammatory skin transcriptomic profile in patients with atopic dermatitis (2022) (0)
- 26313 Efficacy and safety of dupilumab for up to 1 year in a phase 3 open-label extension (OLE) trial (LIBERTY AD PED-OLE) in adolescents with uncontrolled, moderate-to-severe atopic dermatitis (AD) (2021) (0)
- ABSTRACTS | Epidermal Structure & Barrier Function (2015) (0)
- 917 Frontal fibrosing alopecia scalp profiling links Th1/Th2 and JAK3 activation with fibrosis and loss of follicular stem cells (2019) (0)
- [Psoriasis as an immunological disease: pathogenic and therapeutic aspects]. (2000) (0)
- 1312 Heterogeneities in proteomic profiles among African American and East African patients with atopic dermatitis (2023) (0)
- 1315 An Integrated model of alopecia areata biomarkers highlights both Th1/Th2 upregulation, with stronger correlations between Th2 activation and disease severity (2018) (0)
- 1187 Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, reduces immune biomarkers in active lesions and increases melanocyte products in stable lesions in patients with non-segmental vitiligo (NSV) (2023) (0)
- 371 The OX40/OX40L axis plays a key role in treg dysfunction in atopic dermatitis (2023) (0)
- ASN002 demonstrates efficacy and improves inflammation in AD (2019) (0)
- Systemic Manifestations of Atopic Dermatitis: A Systematic Review (2017) (0)
- 428 Randomized, double-blind, placebo-controlled study of efficacy and safety of secukinumab to treat adults with ichthyoses (2021) (0)
- 177 Chronic graft-versus-host disease exhibits distinct Th1-skewing and barrier abnormalities in the skin (2023) (0)
- No association between dupilumab use and short-term cancer development in atopic dermatitis patients. (2022) (0)
- Atopic dermatitis induced during anti-TNF-α therapy for inflammatory bowel disease: Potential for Th2 inhibition with dupilumab. (2023) (0)
- This information is current as Cutaneous Contact Hypersensitivity Inducible Nitric Oxide Synthase To Promote Monocytes / Macrophages Upregulates Arginase 1 Deficiency in (2017) (0)
- Whole Genome Sequencing Identifies Four Novel Variants in the Epidermal Differentiation Complex That Increase Risk and Severity for Atopic Dermatitis (2017) (0)
- Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events (2023) (0)
- Systemic Therapy of Atopic Dermatitis: When, How, for How Long? (2017) (0)
- Allergen Sensitivity in Adults with Atopic Dermatitis (2017) (0)
- Treatment with tralokinumab improves health-related quality of life in adult patients with moderate to severe atopic dermatitis: results from a Phase 2b, randomised, double-blind, placebo-controlled study (2018) (0)
- Supplemental Methods and Results for "Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlledmultiple-dose study" (2019) (0)
- Impact of Vaccination against SARS-CoV-2 on the Atopic Dermatitis Serum Proteome (2022) (0)
- 573 Arginase1/Nos2 imbalance in macrophages mediates cutaneous contact hypersensitivity responses (2017) (0)
- 837 Untargeted lipidomics and transcriptomics suggest role of ceramide increases in congenital ichthyosis phenotypes (2023) (0)
- Reply: To PMID 25748064. (2015) (0)
- 370 Functional regulatory variants for an EDC enhancer in atopic dermatitis converge on skin developmental Kruppel-like and AP1 family transcription factor binding sites (2016) (0)
- Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome towards nonlesional and normal skin. (2023) (0)
- Dupilumab in moderate-to-severe atopic dermatitis: results from two randomized phase 3 trials (SOLO 1 & 2) (2017) (0)
- Atopic Dermatitis Yardstick Update. (2023) (0)
- 3. Contact Dermatitis (2015) (0)
- 1016 Single-cell RNA-sequencing provides novel cell-specific molecular profiling in skin of atopic dermatitis patients and controls (2019) (0)
- 1624 Phenotypic and endotypic determinants of atopic dermatitis severity from the ADRN registry (2023) (0)
- Response to ‘Lack of efficacy of dupilumab in the treatment of keloid disorder’ by MH Tirgan and J Uitto (2021) (0)
- 206 The distinct skin microbiota of congenital ichthyoses (2021) (0)
- Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges [Corrigendum] (2021) (0)
- 118 Ichthyosis transcriptome reveals increased atherosclerosis markers and immune and barrier differences amongst subtypes (2021) (0)
- Filaggrin Associated Risk for Atopic Dermatitis Is Offset By Protective Missense Variants in Rptn and LCE1B Genes in the Epidermal Differentiation Complex (2016) (0)
- [Prologue]. (2018) (0)
- 424 C10orf99 governs keratinocyte inflammatory response and barrier formation of the skin (2022) (0)
- Proteomic Profiling of Atopic Dermatitis, Psoriasis, and Contact Dermatitis Patients (2016) (0)
- Defining a Minimal Effective Serum Trough Concentration of Secukinumab in Psoriasis: A Step toward Personalized Therapy (0)
- The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. (2023) (0)
- Iconographies supplémentaires de l'article : The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased T H 17 polarization (2015) (0)
- Human and computational models of atopic dermatitis (2018) (0)
- 16428 Lebrikizumab, a high-affinity interleukin-13 inhibitor, improves clinical manifestations in moderate to severe atopic dermatitis: Time course of response from a randomized, double-blinded, placebo-controlled, dose-ranging, phase 2b study (2020) (0)
- RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis (2021) (0)
- 207 Targeting of HDAC8 and HDAC9 in keratinocytes to enhance skin immune defense (2021) (0)
- Oral Difelikefalin Reduces Atopic Dermatitis–Associated Pruritus (2022) (0)
- Eosinophil count, serum CCL17/18/26 and immunoglobulin E levels in atopic dermatitis: upadacitinib phase 2 study analysis (2020) (0)
- 555 Integrating serum and skin biomarkers to assess disease extent beyond clinical scores, advancing precision therapeutics (2018) (0)
- Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab (2022) (0)
- Prevalence and Burden of Atopic Dermatitis Involving the Head, Neck, Face, and Hand: A Cross Sectional Study from the TARGET-DERM AD Cohort (2023) (0)
- Impact of vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the atopic dermatitis serum proteome (2022) (0)
- 241 C. Acnes IA1 Phylotype induces features of acneic skin when applied on 3D in vitro model (2020) (0)
- 176 C10orf99/2610528A11Rik induces keratinocyte proinflammatory response and regulates lipid metabolism and barrier formation of the skin (2022) (0)
- 1561 Immune profiling of immune checkpoint inhibitor-induced lichen planus and vitiligo in the setting of pathogenesis-directed therapy (2023) (0)
- 298 RNA-seq profiling highlights the robust inflammation and Th17-skewing of the non-lesional Asian atopic dermatitis phenotype (2017) (0)
- 641 Age-specific changes in normal skin barrier and immunity (2019) (0)
- Dr. Emma Guttman-Yassky (2019) (0)
- Tu1454: THE SAFETY PROFILE OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS IN THE PHASE 3 U-ACHIEVE STUDY IS CONSISTENT WITH THAT IN APPROVED INDICATIONS (2022) (0)
- 33993 Oral difelikefalin improves itch and quality of life in subjects with itch-dominant atopic dermatitis: Subgroup analysis of a randomized, phase 2 study (2022) (0)
- 230 A mild topical steroid leads to progressive anti-inflammatory effects in skin of moderate-to-severe atopic dermatitis (2016) (0)
- 27082 Upadacitinib in moderate-to-severe atopic dermatitis: Combined safety analysis of phase 3 studies (Measure Up 1, Measure Up 2, and AD Up) (2021) (0)
- Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry. (2023) (0)
- 892 Atopic dermatitis endotypes based on allergen sensitization, staphylococcus reactivity, and underlying systemic inflammation (2018) (0)
- 063 The role of OX40/OX40L axis in atopic dermatitis (2023) (0)
- Issue Information (2021) (0)
- 031 Tape strips better capture epidermal barrier abnormalities of patients with atopic dermatitis compared to skin biopsies (2022) (0)
- 568 Comparing molecular cutaneous improvement in atopic dermatitis with various treatment modalities facilitates personalized approaches (2020) (0)
- Supplementary Tables for "The proteomic skin profile of moderate-to-severe atopic dermatitis shows an inflammatory and cardiovascular signature" (2020) (0)
- Shedding light on key pharmacological knowledge and strategies for pediatric atopic dermatitis (2023) (0)
- Molecular characterization of atopic dermatitis: a meta-analysis (2016) (0)
- The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins (2017) (0)
- Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery (2022) (0)
- Oral Presentations (2013) (0)
- 993 Molecular abnormalities of early-onset pediatric atopic dermatitis are captured by tape strips (2019) (0)
- 253 RNA-seq profiling of tape strips from infants with atopic dermatitis show profound barrier and immune abnormalities (2020) (0)
- 552 Transitions in blood immune profile in atopic dermatitis from infancy to adulthood (2023) (0)
- 642 The serum proteomic signature of pediatric AD suggests early Th2/Th17 skewing and an inverse correlation of disease severity with Th1 markers (2017) (0)
- 419 GTEx-skin eQTLs and uncommon variants associated with decreased Involucrin expression are enriched with FLG LOF variants in atopic dermatitis (2019) (0)
- 1318 Both lesional and non-lesional skin from acne patients shows robust IL-17-skewing and upregulation of antimicrobial peptides (2018) (0)
- GBR 830 Induced Progressive and Sustained Improvements in Atopic Dermatitis Skin Biomarkers and Clinical Parameters (2018) (0)
- 330 Safety of abrocitinib in 3582 patients with moderate-to-severe atopic dermatitis with over 900 patients exposed for almost 2 years (2023) (0)
- 408 Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to 5 years with moderate-to-severe atopic dermatitis (2022) (0)
- 425 RNA-seq transcriptomic profiling of diffuse and limited cutaneous systemic sclerosis (2019) (0)
- Alopecia Areata: A Complex Cytokine Driven Disease. (2020) (0)
- 885 Human and mouse experiments identify a role for Th1, Th2, and IL-23 cytokine pathways in the pathogenesis of alopecia areata (2017) (0)
- Tc 2 cells are associated with alopecia areata severity (2017) (0)
- CASESOF THE YEAR C-1 ANUNUSUAL LIPODYSTROPHY SYNDROME IN TWO SIBLINGS: AN ASSOCIATION BETWEEN PROTEASOME- ASSOCIATED AUTOINFLAMMATORY SYNDROMEAND HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS? (2017) (0)
- 124 Lipidomic analysis of congenital ichthyotic skin suggests disruption in ceramide catabolism (2021) (0)
- 069 Non-supervised gene expression profiling of circulating regulatory T cells in severe Korean atopic dermatitis patient by scRNA-seq (2022) (0)
- 410 Tape-strips capture gene-expression changes in moderate-to-severe atopic dermatitis patients treated with dupilumab (2021) (0)
- Age of onset defines two distinct profiles of atopic dermatitis in adults. (2023) (0)
This paper list is powered by the following services:
Other Resources About Emma Guttman-Yassky
What Schools Are Affiliated With Emma Guttman-Yassky?
Emma Guttman-Yassky is affiliated with the following schools:
